Pancreatic Cancer Research

ResearcherTohoku UniversityActive in the last 2 years

Kyohei Ariake

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7261-4349; OpenAlex author ID A5086204781. Sources: OpenAlex.

Their work

Papers
27 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
73
Papers, trials and grants by year

2017: 4 papers · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 8 papers · 2022: 1 paper · 2023: 1 paper · 2024: 5 papers · 2025: 1 paper · 2026: 1 paper

Papers 27

  1. Predictive Factors for Occult Metastases in Clinically M0 Pancreatic Cancer: A Prospective Multicenter Analysis of Staging Laparoscopy. Co-author DOI 10.1245/s10434-026-20728-8↗
  2. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  3. GFPT2 expression is induced by gemcitabine administration and enhances invasion by activating the hexosamine biosynthetic pathway in pancreatic cancer. First author DOI 10.1007/s10585-024-10298-y↗
  4. Deep learning predicts the 1-year prognosis of pancreatic cancer patients using positive peritoneal washing cytology. Co-author DOI 10.1038/s41598-024-67757-5↗
  5. Postoperative Carbohydrate Antigen 19-9 Level as a Good Indicator of Ineffective Response to the Currently Recommended S-1 Adjuvant Chemotherapy for Pancreatic… Co-author DOI 10.1245/s10434-023-14440-0↗
  6. ASO Author Reflections: Postoperative Carbohydrate Antigen 19-9 Levels Become a Reliable Biomarker for Establishing Intensity-Stratified Adjuvant Treatments in… Co-author DOI 10.1245/s10434-023-14506-z↗
  7. [A Case of Unresectable Locally Advanced Pancreatic Cancer in Which Chemoradiotherapy Achieved Pathological Complete Response]. First author PMID 39948838↗
  8. Reduced expression of phosphorylated ataxia-telangiectasia mutated gene is related to poor prognosis and gemcitabine chemoresistance in pancreatic cancer. Co-author DOI 10.1186/s12885-023-11294-3↗
  9. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  10. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Co-author DOI 10.1007/s00595-020-02121-4↗
  11. Silencing of LRRFIP1 enhances the sensitivity of gemcitabine in pancreatic cancer cells by activating JNK/c-Jun signaling. Co-author DOI 10.1016/j.pan.2021.02.018↗
  12. Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer. First author DOI 10.1038/s41598-021-86099-0↗
  13. Ral GTPase-activating protein regulates the malignancy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.14970↗
  14. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up… Co-author DOI 10.1245/s10434-021-09718-0↗
  15. ASO Author Reflections: Preceding Systemic Chemotherapy Might Provide Better Prognosis for Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology. Co-author DOI 10.1245/s10434-021-09755-9↗
  16. Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a P… Co-author DOI 10.3389/fonc.2021.646141↗
  17. Stomatin‑like protein 2 induces metastasis by regulating the expression of a rate‑limiting enzyme of the hexosamine biosynthetic pathway in pancreatic cancer. First author DOI 10.3892/or.2021.8041↗
  18. Prognostic indicators in pancreatic cancer patients undergoing total pancreatectomy. First author DOI 10.1007/s00595-019-01924-4↗
  19. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.08.022↗
  20. Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer. Co-author DOI 10.1007/s00595-019-01842-5↗
  21. Conversion surgery for positive peritoneal washing cytology in pancreatic cancer. First author DOI 10.1136/bcr-2019-229993↗
  22. 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-017-3627-3↗
  23. Association between chronological depressive changes and physical symptoms in postoperative pancreatic cancer patients. Co-author DOI 10.1186/s13030-018-0132-1↗
  24. Predictive risk factors for peritoneal recurrence after pancreatic cancer resection and strategies for its prevention. Co-author DOI 10.1007/s00595-017-1531-9↗
  25. Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed … Co-author DOI 10.1186/s40792-017-0290-6↗
  26. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver m… Co-author DOI 10.1186/s40792-017-0409-9↗
  27. [Multidisciplinary Therapy with Gemcitabine and Nab-Paclitaxel for Unresectable Pancreatic Cancer]. Co-author PMID 29394594↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michiaki Unno · 23 shared papers, 2017–2026 · strength 2.71
  2. Masamichi Mizuma · 20 shared papers, 2017–2026 · strength 2.39
  3. Fuyuhiko Motoi · 16 shared papers, 2017–2026 · strength 1.67
  4. Kei Nakagawa · 15 shared papers, 2017–2024 · strength 1.54
  5. Shimpei Maeda · 14 shared papers, 2017–2026 · strength 1.43
  6. Takanori Morikawa · 11 shared papers, 2017–2023 · strength 1.02
  7. Tatsuyuki Takadate · 9 shared papers, 2017–2021 · strength 0.71
  8. Daisuke Douchi · 4 shared papers, 2021–2024 · strength 0.63
  9. Takashi Tsuchiya · 3 shared papers, 2024 · strength 0.63
  10. Shuichi Aoki · 4 shared papers, 2020–2026 · strength 0.54
  11. Masahiro Iseki · 4 shared papers, 2017–2026 · strength 0.49
  12. Katsutaka Mitachi · 4 shared papers, 2019–2021 · strength 0.45
  13. Takaho Okada · 2 shared papers, 2024 · strength 0.39
  14. Jingyu Xun · 2 shared papers, 2023–2024 · strength 0.36
  15. Tatsuo Hata · 4 shared papers, 2017–2021 · strength 0.34
  16. Toru Furukawa · 2 shared papers, 2023–2024 · strength 0.32
  17. Sohei Satoi · 2 shared papers, 2022–2025 · strength 0.30
  18. Itaru Endo · 2 shared papers, 2022–2025 · strength 0.30
  19. Kei Kawaguchi · 3 shared papers, 2018–2021 · strength 0.27
  20. Takayuki Morito · 1 shared paper, 2024 · strength 0.24
  21. Nana Kimura · 1 shared paper, 2026 · strength 0.23
  22. Takamichi Igarashi · 1 shared paper, 2026 · strength 0.23
  23. Katsuhisa Hirano · 1 shared paper, 2026 · strength 0.23
  24. Shingo Yoshimachi · 2 shared papers, 2020–2021 · strength 0.20
  25. Kent Miyazaki · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.